Therapeutic compositions comprising imidazole and imidazolium compounds
AssigneeAntecip Bioventures II LLC
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Therapeutic compositions comprising substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain.
Claims21
A method of treating musculoskeletal pain comprising orally administering a pharmaceutical composition to a mammal in need thereof, wherein the pharmaceutical composition comprises:
- in an amount that is less than 0.1% w/w, and greater than 0%;
- or
- in an amount that is less than 0.1% w/w, and greater than 0% w/w;
- wherein any amount in % w/w is based upon the total weight of Compound A, Compound B, and Compound C;
- wherein each A is independently an acidic functional group.
A method of treating joint pain not associated with cancer comprising orally administering a pharmaceutical composition to a human being suffering from joint pain not associated with cancer, wherein the pharmaceutical composition comprises:
- a) zoledronic acid;
- or
- b) one of the following:
- 1) zoledronic acid and
- in an amount that is less than 0.1% w/w and greater than 0% w/w;
- 2) zoledronic acid and
- in an amount that is less than 0.1% w/w and greater than 0% w/w;
- or
- 3) zoledronic acid and a combination of Compound 1 in an amount that is less than 0.1% w/w and greater than 0% w/w, and Compound 2 in an amount that is less than 0.1% w/w and greater than 0% w/w;
- wherein the pharmaceutical composition is free of therapeutically active agents that are not zoledronic acid, Compound 1, and Compound 2;
- wherein any amount in % w/w is based upon the total weight of zoledronic acid, Compound 1, and Compound 2;
- and
- wherein the bioavailability of zoledronic acid in the dosage form is about 1.1% to about 4%.
A method of treating complex regional pain syndrome comprising orally administering a pharmaceutical composition to a human being suffering from complex regional pain syndrome, wherein the pharmaceutical composition comprises:
- a) zoledronic acid;
- or
- b) one of the following:
- 1) zoledronic acid and
- in an amount that is less than 0.1% w/w and greater than 0% w/w;
- 2) zoledronic acid and
- in an amount that is less than 0.1% w/w and greater than 0% w/w;
- or
- 3) zoledronic acid and a combination of Compound 1 in an amount that is less than 0.1% w/w and greater than 0% w/w, and Compound 2 in an amount that is less than 0.1% w/w and greater than 0% w/w;
- wherein the pharmaceutical composition is free of therapeutically active agents that are not zoledronic acid, Compound 1, and Compound 2;
- wherein any amount in % w/w is based upon the total weight of zoledronic acid, Compound 1, and Compound 2;
- and
- wherein the bioavailability of zoledronic acid in the dosage form is about 1.1% to about 4%.
A method of treating ankylosing spondylitis comprising orally administering a pharmaceutical composition to a human being suffering from ankylosing spondylitis, wherein the pharmaceutical composition comprises:
- a) zoledronic acid;
- or
- b) one of the following:
- 1) zoledronic acid and
- in an amount that is less than 0.1% w/w and greater than 0% w/w;
- 2) zoledronic acid and
- in an amount that is less than 0.1% w/w and greater than 0% w/w;
- or
- 3) zoledronic acid and a combination of Compound 1 in an amount that is less than 0.1% w/w and greater than 0% w/w, and Compound 2 in an amount that is less than 0.1% w/w and greater than 0% w/w;
- wherein the pharmaceutical composition is free of therapeutically active agents that are not zoledronic acid, Compound 1, and Compound 2;
- wherein any amount in % w/w is based upon the total weight of zoledronic acid, Compound 1, and Compound 2;
- and
- wherein the bioavailability of zoledronic acid in the dosage form is about 1.1% to about 4%.
Dependencies are inferred from the claim text.